Nash Videos

▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.

AllComorbiditiesDefinitionDiagnosisEpidemiologyManagementNash TreatmentPathophysiologyPPAR Agonists
Dr. Maarten E Tushuizen

GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 1)

Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.
View More ⏩GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 1)
5Th Global Nash Congress

5Th Global Nash Congress

This slides set presents a detailed review of vascular alterations in non-alcoholic steatohepatitis (NASH) and NASH cirrhosis delivered by Professor Francque, MD, PhD. He highlights that non-fibrotic non-alcoholic fatty liver disease (NAFLD) is accompanied by a significant rise in portal pressure. Professor Francque, also explains the effects of intrahepatic vascular resistance increase in NAFLD. To the clinicians, he provides various patient studies, statistics and clinical data on the subject.
View More ⏩5Th Global Nash Congress
pannash Webinar -2

Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

This multidisciplinary discussion on the diabetologist's and hepatologist's perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.
View More ⏩Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

Non-Invasive Evaluation of NAFLD Severity

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
View More ⏩Non-Invasive Evaluation of NAFLD Severity

NAFLD/NASH as a metabolic disease: improving patients outcomes

Prof. Maarten Tushuizen, Netherlands, discusses the current treatment strategies for non-alcoholic fatty liver disease (NAFLD) and explains as well as future therapeutic approaches. Non-invasive tests (NITs) for staging the continuum of NAFLD / NASH are critical as well as establishing effective care pathways.
View More ⏩NAFLD/NASH as a metabolic disease: improving patients outcomes

Interactions between gut microbiota and PPARs in NAFLD

Dr. Nicolas Lanthier (Belgium) reviews the interaction between the gut microbiota and PPARs in NAFLD. He discusses the microbiota and its link to NAFLD and IR, where he explains the key role of the gut microbes in the metabolism of their host and highlights how liver becomes the first organ to be exposed to gut changes.
View More ⏩Interactions between gut microbiota and PPARs in NAFLD

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES